Cabometyx

(Cabozantinib)

ApprovedSmall molecule

Cabozantinib is used to treat certain types of cancer, including kidney cancer, liver cancer, and thyroid cancer. It works by blocking proteins that help cancer cells grow and spread.[2] Cabometyx is currently approved and in use across 63 indications[4].[1]

Cabometyx is one of 610 small molecule programs targeting Liver Cancer. It is currently in Approved.

Indications

248

Total Trials

Active Trials

609

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Liver CancerRecruiting

Thyroid CancerNot yet recruiting

Metastatic Renal Cell CarcinomaRecruiting

Locally AdvancedTerminated

Refractory Solid TumorsActive, not recruiting

Bladder Small Cell Neuroendocrine CarcinomaActive, not recruiting

High Grade Neuroendocrine NeoplasmsActive, not recruiting

Malignant Neoplasms of Urinary TractActive, not recruiting

Bladder Urothelial CarcinomaActive, not recruiting

Castration-Resistant Prostate CarcinomaActive, not recruiting

Liver CancerPhase 2

Recruiting

Thyroid CancerApproved

Not yet recruiting

Metastatic Renal Cell CarcinomaPhase 2

Recruiting

Locally AdvancedPhase 2

Terminated

Refractory Solid TumorsPhase 1

Active, not recruiting

Bladder Small Cell Neuroendocrine CarcinomaPhase 1

Active, not recruiting

High Grade Neuroendocrine NeoplasmsPhase 2

Active, not recruiting

Malignant Neoplasms of Urinary TractPhase 2

Active, not recruiting

Bladder Urothelial CarcinomaPhase 3

Active, not recruiting

Castration-Resistant Prostate CarcinomaPhase 2

Active, not recruiting

Showing 10 of 63 indications

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Cabometyx

Bristol-Myers Squibb

Approved

9 2

Iza-Bren

Bristol-Myers Squibb

Phase 3

3 3

YL202

MMediLink Therapeutics (Suzhou) Co., Ltd.

Phase 3

3 4

Gotistobart

OOncoC4, Inc.

Phase 3

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Renal Cell Carcinoma

NCT02293980

Phase 2Active, not recruiting

Melanoma

NCT04091750

Phase 2Recruiting

Temozolomide

NCT04893785

Phase 1Active, not recruiting

Neuroendocrine Tumors

NCT05249114

Phase 2Not yet recruiting

Hepatocellular Carcinoma

NCT06535737

Phase 1Recruiting

Metastatic Urothelial Cancer

NCT04878029

Clinical

Trials by Indication[1]

Renal Cell Carcinoma20 trials

A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT06132945·2 enrolled

Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases

Completed·CCentre Leon Berard·Phase 2·NCT03967522·26 enrolled

Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

Completed· Ipsen logo

Ipsen··NCT04353765·247 enrolled

Show 17 more trials

Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma

Completed· Takeda logo

Takeda··NCT04804813·388 enrolled

A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma

Terminated·GGenenta Science·Phase 1/2·NCT06716853·10 enrolled

Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma

Unknown status·IIstituto Oncologico Veneto IRCCS··NCT04416646·100 enrolled

Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

Completed·UUniversity of Colorado, Denver·Phase 1/2·NCT03149822·45 enrolled

Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 4·NCT06934057·50 enrolled

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)

Completed·UUniversity of Utah·Phase 1·NCT03200587·12 enrolled

A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

Terminated· Roche logo

Roche·Phase 3·NCT04338269·522 enrolled

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Terminated·NNektar Therapeutics·Phase 3·NCT03729245·623 enrolled

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

Completed·CCalithera Biosciences, Inc·Phase 2·NCT03428217·444 enrolled

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma

Completed· Takeda logo

Takeda·Phase 2·NCT03339219·35 enrolled

caBozantinib in cOllectiNg ductS Renal Cell cArcInoma

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03354884·23 enrolled

Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib

Recruiting·GGruppo Oncologico Italiano di Ricerca Clinica··NCT06548867·80 enrolled

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT03634540·118 enrolled

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT02293980·110 enrolled

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma

Completed·EExelixis·Phase 3·NCT01865747·658 enrolled

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Terminated·AAravive, Inc.·Phase 1/2·NCT04300140·72 enrolled

A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk

Active, not recruiting·EExelixis·Phase 3·NCT03937219·855 enrolled

Hepatocellular Carcinoma17 trials

Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)

Completed·FFundacion Clinic per a la Recerca Biomédica·Phase 2·NCT04316182·24 enrolled

Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

Withdrawn·OOHSU Knight Cancer Institute·Phase 2·NCT05327738

Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)

Completed·HHospices Civils de Lyon·Phase 4·NCT03963206·110 enrolled

Show 14 more trials

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma

Completed· Takeda logo

Takeda·Phase 2·NCT03586973·34 enrolled

Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04511455·22 enrolled

Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma

Completed· Takeda logo

Takeda··NCT05100082·263 enrolled

A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function

Unknown status·JJohannes Gutenberg University Mainz·Phase 2·NCT04454762·20 enrolled

A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab

Not yet recruiting·—·Phase 2·NCT06535737·40 enrolled

Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT04497038·3 enrolled

Cabozantinib in Hepatocellular Carcinoma

Active, not recruiting·SStephen Chan Lam·Phase 2·NCT04588051·20 enrolled

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

Active, not recruiting·EExelixis·Phase 3·NCT03755791·837 enrolled

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

Recruiting·IIterion Therapeutics·Phase 1/2·NCT05797805·178 enrolled

Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors

Completed·UUniversity of Leipzig·Phase 2·NCT04767906·16 enrolled

Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT03299946·15 enrolled

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Completed·EExelixis·Phase 3·NCT01908426·707 enrolled

Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma

Unknown status·IIstituto Clinico Humanitas·Phase 2·NCT04435977·46 enrolled

Phase 2 Study of Cabozantinib Combined With Ipilimumab/Nivolumab and Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC) Who Are Not Candidates for Curative Intent Treatment

Recruiting·UUniversity of California, Irvine·Phase 2·NCT04472767·35 enrolled

Prostate Cancer11 trials

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Completed·EExelixis·Phase 3·NCT01605227·1,028 enrolled

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

Terminated·—·Phase 2·NCT03964337·3 enrolled

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Terminated·EExelixis·Phase 3·NCT01522443·119 enrolled

Show 8 more trials

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Terminated·UUniversity of Washington·Phase 2·NCT01703065·9 enrolled

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Completed·WWashington University School of Medicine·Phase 1·NCT04477512·18 enrolled

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01683994·49 enrolled

Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

Completed·MMassachusetts General Hospital·Phase 1·NCT01347788·34 enrolled

Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer

Completed·UUniversity of Chicago·Phase 2·NCT01599793·19 enrolled

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT01428219·25 enrolled

A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases

Completed·—·Phase 2·NCT01834651·17 enrolled

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Completed·WWeill Medical College of Cornell University·Phase 2·NCT04631744·4 enrolled

Non-Small Cell Lung Cancer9 trials

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT05613413·36 enrolled

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Terminated·—·Phase 1·NCT04173338·9 enrolled

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

Terminated·LLiza Villaruz, MD·Phase 2·NCT02132598·5 enrolled

Show 6 more trials

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01866410·37 enrolled

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT04151563

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

Completed· Roche logo

Roche·Phase 3·NCT04471428·366 enrolled

CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation

Unknown status·FFondazione Ricerca Traslazionale·Phase 2·NCT03911193·25 enrolled

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03468985·3 enrolled

A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01639508·86 enrolled

Thyroid Cancer8 trials

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Approved for marketing·EExelixis··NCT01683110

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01811212·25 enrolled

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03630120·6 enrolled

Show 5 more trials

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT04211337·291 enrolled

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Recruiting·WWest China Hospital·Phase 2·NCT06482086·75 enrolled

Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Active, not recruiting·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT05660954·41 enrolled

A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

Withdrawn· Roche logo

Roche·Phase 3·NCT04760288

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

Not yet recruiting·FFujian Medical University·Phase 4·NCT07010393·335 enrolled

101 more indications

Kidney Cancer7 trials

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02761057·152 enrolled

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Not yet recruiting·SSWOG Cancer Research Network·Phase 3·NCT07383441·718 enrolled

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

Active, not recruiting·—·Phase 1·NCT05122546·31 enrolled

Show 4 more trials

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01835158·157 enrolled

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04540705·30 enrolled

CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

Recruiting·MMark Stein·Phase 2·NCT04322955·48 enrolled

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

Active, not recruiting·EEmory University·Phase 2·NCT04022343·22 enrolled

Trial4 trials

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients

Not yet recruiting·—·Phase 2·NCT05241561·24 enrolled

Show 1 more trial

A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT04427787·69 enrolled

Liver Cancer3 trials

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT04204850·20 enrolled

Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

Terminated·UUniversity of Washington·Phase 2·NCT04442581·2 enrolled

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT01658878·657 enrolled

Advanced Cancer3 trials

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04514484·8 enrolled

Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer

Completed·EExelixis·Phase 1·NCT01553656·85 enrolled

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT05663710·100 enrolled

Soft Tissue Sarcoma2 trials

Cabozantinib for Adults With Advanced Soft Tissue Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01755195·55 enrolled

Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT04551430·105 enrolled

Melanoma2 trials

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01835184·5 enrolled

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Active, not recruiting·GGeorgetown University·Phase 2·NCT04091750·14 enrolled

Multiple Myeloma2 trials

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

Completed·MMassachusetts General Hospital·Phase 1·NCT01582295·4 enrolled

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Terminated·UUniversity of Nebraska·Phase 1/2·NCT03201250·11 enrolled

Metastatic Colorectal Cancer2 trials

caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.

Unknown status·UUniversity of Campania Luigi Vanvitelli·Phase 2·NCT06171854·33 enrolled

Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer

Completed·JJohn Strickler, M.D.·Phase 1·NCT02008383·29 enrolled

Breast Cancer2 trials

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Completed·MMassachusetts General Hospital·Phase 2·NCT01441947·68 enrolled

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Completed·—·Phase 2·NCT02260531·36 enrolled

Adrenocortical Carcinoma2 trials

Cabozantinib in Advanced Adrenocortical Carcinoma

Unknown status·WWuerzburg University Hospital·Phase 2·NCT03612232·37 enrolled

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03370718·18 enrolled

Metastatic Prostate Cancer2 trials

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·N/A·NCT01812668·20 enrolled

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01630590·62 enrolled

Carcinoid Tumor2 trials

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Completed·—·Phase 2·NCT01466036·61 enrolled

Cabozantinib and Nivolumab for Carcinoid Tumors

Completed·—·Phase 2·NCT04197310·19 enrolled

mCRPC2 trials

Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib

Completed·AAlfredo Berruti·Phase 2·NCT05265988·32 enrolled

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Active, not recruiting·EExelixis·Phase 3·NCT04446117·575 enrolled

Locally Advanced2 trials

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Recruiting·EEmory University·Phase 2·NCT06006013·21 enrolled

Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.

Terminated·JJohannes Gutenberg University Mainz·Phase 2·NCT04066595·7 enrolled

Metastatic Melanoma2 trials

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01835145·47 enrolled

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Terminated·JJohn Rieth·Phase 1/2·NCT03957551·28 enrolled

Head and Neck Squamous Cell Cancer2 trials

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Active, not recruiting·EEmory University·Phase 2·NCT03468218·36 enrolled

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03667482·20 enrolled

Refractory Solid Tumors2 trials

Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

Recruiting·PPeter Zage·Phase 1·NCT03611595·18 enrolled

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05038839·44 enrolled

Pancreatic Cancer2 trials

A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT01663272·12 enrolled

Phase II Trial Evaluating the Safety and Efficacy of Atezolizumab in Combination With Cabozantinib for the Treatment of Metastatic, Refractory Pancreatic Cancer

Completed·UUniversity of Arizona·Phase 2·NCT04820179·32 enrolled

Clear Cell Renal Cell Carcinoma2 trials

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Recruiting· Arcus Biosciences logo

Arcus Biosciences·Phase 1·NCT05536141·362 enrolled

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT03793166·1,175 enrolled

Osteosarcoma2 trials

A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment

Terminated· Ipsen logo

Ipsen·Phase 2·NCT06341712·10 enrolled

A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Suspended·NNational Cancer Institute (NCI)·Preclinical·NCT05691478·1,122 enrolled

Metastatic Renal Cell Carcinoma2 trials

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

Recruiting·NNRG Oncology·Phase 2·NCT05327686·240 enrolled

A Phase 1b/2 Study of Abemaciclib Plus Cabozantinib in Immune Checkpoint Blockade-pretreated Metastatic Clear Cell Renal Cell Carcinoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT06835972·43 enrolled

Bladder Cancer1 trial

Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer

Active, not recruiting·DDeepak Kilari·Phase 2·NCT04289779·46 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Completed·NNational Taiwan University Hospital·Phase 2·NCT05007613·24 enrolled

Endocrine Cancer1 trial

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Completed·MM.D. Anderson Cancer Center·N/A·NCT02592356·23 enrolled

Pediatric Solid Tumors1 trial

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Recruiting·NNationwide Children's Hospital·Phase 2·NCT05135975·86 enrolled

Combination Therapy1 trial

Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy

Not yet recruiting·NNational Health Research Institutes, Taiwan·Phase 2·NCT07151326·60 enrolled

Salivary Gland Cancer1 trial

Cabozantinib in Advanced Salivary Gland Cancer Patients

Terminated·RRadboud University Medical Center·Phase 2·NCT03729297·25 enrolled

Endometrial Cancer1 trial

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01935934·102 enrolled

Temozolomide1 trial

A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)

Recruiting·NNational Cancer Institute, Naples·Phase 2·NCT04893785·35 enrolled

Primary Peritoneal Cavity Cancer1 trial

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01716715·111 enrolled

Recurrent or Refractory Solid Tumors1 trial

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01709435·41 enrolled

Primary Peritoneal Cancer1 trial

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02315430·13 enrolled

Radiation Therapy1 trial

Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

Terminated·UUniversity of Washington·Phase 1/2·NCT04220229·6 enrolled

Metastatic Urothelial Cancer1 trial

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Recruiting·EEmory University·Phase 1·NCT04878029·32 enrolled

Cervical Cancer1 trial

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Terminated·UUniversity of South Alabama·Phase 2·NCT04230954·5 enrolled

Paraganglioma1 trial

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02302833·21 enrolled

Immunodeficiency1 trial

Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01822522·36 enrolled

Neuroendocrine Tumors1 trial

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Active, not recruiting·PProvidence Health & Services·Phase 1·NCT05249114·6 enrolled

Triple Negative1 trial

Cabozantinib for Metastatic Triple Negative BrCa

Completed·—·Phase 2·NCT01738438·35 enrolled

Cytoreductive Nephrectomy1 trial

Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer

Terminated·FFundacion Oncosur·Phase 2·NCT06377722·18 enrolled

Cholangiocarcinoma1 trial

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

Completed·MMassachusetts General Hospital·Phase 2·NCT01954745·19 enrolled

Acute Myeloid Leukemia1 trial

Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·MMassachusetts General Hospital·Phase 1·NCT01961765·18 enrolled

Immunotherapy1 trial

ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)

Completed·AAustralian and New Zealand Urogenital and Prostate Cancer Trials Group·Phase 2·NCT03685448·35 enrolled

Advanced Urothelial Cancer1 trial

Cabozantinib for Advanced Urothelial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01688999·69 enrolled

Merkel Cell Carcinoma1 trial

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

Terminated·—·Phase 2·NCT02036476·8 enrolled

Relapse1 trial

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Terminated·EExelixis·Phase 2·NCT01068782·19 enrolled

Metastatic NSCLC1 trial

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

Not yet recruiting·JJun Zhang, MD, PhD·Phase 2·NCT05859217·40 enrolled

Differentiated Thyroid Carcinoma1 trial

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Unknown status·TThomas Jefferson University·Phase 2·NCT02041260·43 enrolled

Advanced Stage1 trial

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Recruiting·HHumanity & Health Medical Group Limited·Phase 2·NCT03899428·30 enrolled

Durvalumab1 trial

hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03824691·122 enrolled

Treatment1 trial

Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England

Completed· Ipsen logo

Ipsen··NCT04637204·1,540 enrolled

Squamous Cell Carcinoma1 trial

Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03943602·37 enrolled

Pembrolizumab1 trial

Cabozantinib and Pembrolizumab in Metastatic Pancreas

Completed·JJoseph Kim·Phase 2·NCT05052723·21 enrolled

Renal Carcinoma1 trial

Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study

Completed·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT04134390·25 enrolled

Cutaneous Melanoma1 trial

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Terminated·PProvidence Health & Services·Phase 2·NCT05200143·4 enrolled

Active, not recruiting·KKarsten Gavenis·Phase 2·NCT04524208·45 enrolled

Triple-Negative Breast Cancer1 trial

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Completed·—·Phase 2·NCT03316586·18 enrolled

Advanced Malignancies1 trial

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Completed·EExelixis·Phase 2·NCT00940225·730 enrolled

Central Nervous System Tumor1 trial

Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

Terminated·IIndiana University·Phase 2·NCT02885324·4 enrolled

Adult Subject1 trial

Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects

Completed·EExelixis·Phase 1·NCT01493869·26 enrolled

Renal Cancer1 trial

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Completed· Novartis logo

Novartis·Phase 1·NCT03798626·167 enrolled

Clinical Trial1 trial

CARE1 Pragmatic Clinical Trial

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT06364631·1,250 enrolled

Advanced Solid Malignancies1 trial

Cabozantinib in Advanced Solid Malignancies

Completed·MMassachusetts General Hospital·Phase 2·NCT01588821·37 enrolled

Pancreatic Neuroendocrine Tumor1 trial

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Recruiting·NNational Health Research Institutes, Taiwan·Phase 1/2·NCT05048901·49 enrolled

mCRC1 trial

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Active, not recruiting·UUniversity of California, Irvine·Phase 1·NCT04868773·12 enrolled

Plexiform Neurofibroma1 trial

Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT02101736·45 enrolled

Urothelial Carcinoma1 trial

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma

Completed·UUniversity of Utah·Phase 2·NCT03534804·37 enrolled

Esophageal Cancer1 trial

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

Recruiting·AAnwaar Saeed·Phase 1/2·NCT03539822·117 enrolled

Genomic Alterations1 trial

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT02795156·100 enrolled

Tyrosine Kinase Inhibitor1 trial

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05039736

Chemotherapy1 trial

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Terminated·EExelixis·Phase 2·NCT01995058·54 enrolled

Impaired Renal Function1 trial

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

Completed·EExelixis·Phase 1·NCT01761773·32 enrolled

Colorectal Cancer1 trial

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT04963283·48 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Precision Therapy in Refractory Tumor

Unknown status·BBaodong Qin·Phase 2·NCT03239015·300 enrolled

Meningioma1 trial

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Recruiting·BBaptist Health South Florida·Phase 2·NCT05425004·24 enrolled

Neoplasms1 trial

Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study

Completed·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT04400474·93 enrolled

Pancreatic Adenocarcinoma1 trial

Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

Terminated·PPatrick Joseph Loehrer Sr.·Phase 2·NCT03213626·7 enrolled

Phase II1 trial

Phase II Study With Cabozantinib in Patients With RET Positive NSCLC

Unknown status·UUniversity of Bologna·Phase 2·NCT04131543·25 enrolled

Function1 trial

Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04522908·40 enrolled

Relapsed or Refractory1 trial

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT01866293·11 enrolled

Metastatic Digestive System Neuroendocrine Tumor G11 trial

NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05773274·100 enrolled

Clinical Stage III Cutaneous Melanoma AJCC v81 trial

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05136196·150 enrolled

Leiomyosarcoma1 trial

A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

Active, not recruiting·CCity of Hope Medical Center·Phase 2·NCT04200443·96 enrolled

Metastatic Clear Cell Renal Cell Carcinoma1 trial

A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Recruiting· Arcus Biosciences logo

Arcus Biosciences·Phase 3·NCT07011719·720 enrolled

Castration-resistant Prostate Cancer1 trial

A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

Active, not recruiting·RRana McKay, MD·Phase 2·NCT05502315·47 enrolled

Metastatic Nasopharyngeal Carcinoma1 trial

Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy

Suspended·NNational Cancer Institute (NCI)·Phase 2·NCT05904080·50 enrolled

Bladder Adenocarcinoma1 trial

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03866382·314 enrolled

Renal Cell Carcinoma (RCC)1 trial

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Enrolling by invitation·EExelixis·Phase 3·NCT07620574·5,000 enrolled

Advanced Hepatocellular Carcinoma1 trial

A Phase I/II Trial of Sapanisertib in Combination With Cabozantinib in β-catenin-mutated Hepatocellular Carcinoma (SAPHIRE)

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT06811116·92 enrolled

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma1 trial

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04310007·117 enrolled

Bladder Urothelial Carcinoma1 trial

MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT05092958·654 enrolled

Functioning Pancreatic Neuroendocrine Tumor1 trial

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT03375320·298 enrolled

RCC1 trial

Phase 2, Open-label, Single Cohort, Multicenter Trial for Sequential Treatment of High Dose Cabozantinib on/After Progression on Cabozantinib Monotherapy in Advanced Renal Cell Carcinoma (Seq-Cabo)

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT05931393·18 enrolled

Advanced Renal Cell Carcinoma (RCC)1 trial

ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07293351·474 enrolled

Von Hippel-Lindau Disease1 trial

A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long-term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07405164·450 enrolled

High Grade Neuroendocrine Neoplasms1 trial

Cabozantinib in High Grade Neuroendocrine Neoplasms

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT04412629·35 enrolled

Medullary Thyroid Cancer1 trial

A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients

Active, not recruiting·EExelixis·Approved·NCT01896479·247 enrolled

Unspecified5 trials

XL-184+Abiraterone in Post-Chemo CRPC

Completed·—·Phase 1·NCT01574937·27 enrolled

Spanish Real-World Evidence Cabozantinib

Completed·SSpanish Oncology Genito-Urinary Group··NCT04510688·275 enrolled

Cabozantinib With Topotecan-Cyclophosphamide

Completed·—·Phase 1·NCT04661852·12 enrolled

Show 2 more trials

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03899155·1,500 enrolled

An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)

Active, not recruiting· Roche logo

Roche·Phase 3·NCT03768063·1,000 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 25, 2016

CABOMETYX

NDA NDA208692

Dec 19, 2017

CABOMETYX

NDA NDA208692

Jan 14, 2019

CABOMETYX

NDA NDA208692

Jan 31, 2020

CABOMETYX

NDA NDA208692

Jul 16, 2020

CABOMETYX

NDA NDA208692

Nov 5, 2020

CABOMETYX

NDA NDA208692

Jan 22, 2021

CABOMETYX

NDA NDA208692

Sep 17, 2021

CABOMETYX

NDA NDA208692

Jul 14, 2022

CABOMETYX

NDA NDA208692

Feb 13, 2023

CABOMETYX

NDA NDA208692

Sep 20, 2023

CABOMETYX

NDA NDA208692

Mar 26, 2025

CABOMETYX

NDA NDA208692

Sep 10, 2025

CABOMETYX

NDA NDA208692

Oct 9, 2025

CABOMETYX

NDA NDA208692

Sources

References

[1]
ClinicalTrials.gov — 248 trial records for Cabozantinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Cabometyx drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Cabozantinib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Cabozantinib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA208692). U.S. Food & Drug Administration.
[6]
PubMed — 1 publication indexed for Cabozantinib. U.S. National Library of Medicine.
[7]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Multi-Kinase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Bristol-Myers Squibb

Key Publications[6]

Cabozantinib Plus Nivolumab in Advanced Renal Cell Carcinoma: CheckMate 9ER

N Engl J MedMar 3, 2022DOI: 10.1056/NEJMoa2205821

Cabometyx

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Renal Cell Carcinoma20 trials

Hepatocellular Carcinoma17 trials

Prostate Cancer11 trials

Non-Small Cell Lung Cancer9 trials

Thyroid Cancer8 trials

Kidney Cancer7 trials

Trial4 trials

Liver Cancer3 trials

Advanced Cancer3 trials

Soft Tissue Sarcoma2 trials

Melanoma2 trials

Multiple Myeloma2 trials

Metastatic Colorectal Cancer2 trials

Breast Cancer2 trials

Adrenocortical Carcinoma2 trials

Metastatic Prostate Cancer2 trials

Carcinoid Tumor2 trials

mCRPC2 trials

Locally Advanced2 trials

Metastatic Melanoma2 trials

Head and Neck Squamous Cell Cancer2 trials

Refractory Solid Tumors2 trials

Pancreatic Cancer2 trials

Clear Cell Renal Cell Carcinoma2 trials

Osteosarcoma2 trials

Metastatic Renal Cell Carcinoma2 trials

Bladder Cancer1 trial

Esophageal Squamous Cell Carcinoma1 trial

Endocrine Cancer1 trial

Pediatric Solid Tumors1 trial

Combination Therapy1 trial

Salivary Gland Cancer1 trial

Endometrial Cancer1 trial

Temozolomide1 trial

Primary Peritoneal Cavity Cancer1 trial

Recurrent or Refractory Solid Tumors1 trial

Primary Peritoneal Cancer1 trial

Radiation Therapy1 trial

Metastatic Urothelial Cancer1 trial

Cervical Cancer1 trial

Paraganglioma1 trial

Immunodeficiency1 trial

Neuroendocrine Tumors1 trial

Triple Negative1 trial

Cytoreductive Nephrectomy1 trial

Cholangiocarcinoma1 trial

Acute Myeloid Leukemia1 trial

Immunotherapy1 trial

Advanced Urothelial Cancer1 trial

Merkel Cell Carcinoma1 trial

Relapse1 trial

Metastatic NSCLC1 trial

Differentiated Thyroid Carcinoma1 trial

Advanced Stage1 trial

Durvalumab1 trial

Treatment1 trial

Squamous Cell Carcinoma1 trial

Pembrolizumab1 trial

Renal Carcinoma1 trial

Cutaneous Melanoma1 trial

Uterine Sarcoma1 trial

GIST1 trial

Carcinosarcoma1 trial

Advanced1 trial

Triple-Negative Breast Cancer1 trial

Advanced Malignancies1 trial

Central Nervous System Tumor1 trial

Adult Subject1 trial

Renal Cancer1 trial

Clinical Trial1 trial

Advanced Solid Malignancies1 trial

Pancreatic Neuroendocrine Tumor1 trial

mCRC1 trial

Plexiform Neurofibroma1 trial